← All trials
NCT05879627
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 17, 2023
- Primary completion
- Dec 31, 2024
- Completion date
- Jul 1, 2025
- First posted
- May 30, 2023
- Last posted
- May 30, 2023
- Enrollment
- 42
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BiotheraLead sponsor
- Chinese Academy of Medical SciencesOfficial
- Zhejiang UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.